Develops iron-activated drug conjugates (FeADCs) that exploit ferroptosis and ferro-addiction in tumors to deliver targeted cancer therapies. This approach addresses the challenge of treating resistant tumors by selectively inducing cell death in iron-dependent cancer cells while sparing healthy tissue.
Funding
Funding not disclosed
Founders
Product
Problem
Many tumors, particularly those with RAS mutations, are difficult to treat and exhibit resistance to conventional therapies, leading to significant morbidity and mortality. These resistant tumors often display an elevated concentration of ferrous iron, which correlates with shorter survival times. Current treatments often lack the specificity needed to target cancer cells effectively, resulting in significant side effects due to activity in healthy tissues.
Solution
Tatara Therapeutics is developing iron-activated drug conjugates (FeADCs) that selectively target and destroy cancer cells by exploiting their dependence on iron. The FeADCs are designed to be activated only in the presence of high concentrations of ferrous iron, a characteristic of many aggressive tumors. This targeted activation minimizes off-target effects and reduces toxicity to healthy tissues. By leveraging the unique metabolic vulnerabilities of cancer cells, Tatara's approach aims to improve treatment outcomes and quality of life for patients with resistant tumors. The company's lead candidate, TRX-cobimetinib, is a modified version of cobimetinib bearing a molecular sensor of ferrous iron, effectively turning the drug on only when it encounters ferrous iron in cancer cells.
Target Audience
The primary target audience includes patients with RAS-mutated cancers and other iron-addicted tumors that are resistant to conventional therapies, as well as oncologists seeking more effective and less toxic treatment options.
Features
- Iron-activated drug conjugate (FeADC) platform for targeted cancer therapy
- Selective activation in tumors with high ferrous iron concentrations
- Reduced toxicity and off-target effects compared to conventional chemotherapies
- Tunable drug release based on ferrous iron levels within the tumor microenvironment
- Potential for combination therapies with synergistic anticancer drugs